Genescience Pharmaceuticals Co., Ltd.
rhGH (rDNA origin) for injection / Jintropin®Somatropin
• First rhGH on Chinese market; launched in 1998
• Over 25,000 patients treated in China during the last 7 years, no unexpected side effects
• Dominant brand of rhGH in China with 70% of market share
• Unique production technology with E.coli secretion expression system
• The only 191-aa hGH made by secretion technology patented in China
• Largest production capability and best quality in Asia
• Internal quality control standards higher than that of Chinese Pharmacopoeia 2005 and European Pharmacopoeia 2005
• First approval in the world to treat burns
• First in the world to develop topical formulation, oral formulation and long-acting formulation
Clinical Indications:
• Child growth
• Burns
• Adult growth hormone deficiency
Contact Details
|
Genescience Pharmaceuticals Co., Ltd. No.72 Tianhe Rd, High & New Technology Development Zone Tel: 86-431-85195060 Fax: 86-431-85186819 Email: export@gensci-china.com
Homepage Address http://www.gensci-china.com |
Key Contact: Mr. Frank Liu |
